mutant + WT CFTR Cl channel potentiator
oral 300 mg BID , Ph. II in COPD and CF
from 1M cmpd cell-based HTS + opt.
J. Med. Chem., May 24, 2021
Millenium/Takeda, Cambridge, MA
The Novartis mutant and WT CFTR potentiator, icenticaftor (QBW251), is an oral Ph. II clinical candidate for chronic obstructive pulmonary disease (COPD), which is anticipated to become the 3rd leading cause…